Huntington National Bank Holds Position in Bristol-Myers Squibb Co. (BMY)
Huntington National Bank continued to hold its stake in Bristol-Myers Squibb Co. (NYSE:BMY) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 725,740 shares of the biopharmaceutical company’s stock at the end of the second quarter. Bristol-Myers Squibb makes up approximately 1.1% of Huntington National Bank’s holdings, making the stock its 11th largest position. Huntington National Bank’s holdings in Bristol-Myers Squibb were worth $46,811,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of BMY. Williams Jones & Associates LLC increased its stake in Bristol-Myers Squibb by 1.6% in the first quarter. Williams Jones & Associates LLC now owns 396,296 shares of the biopharmaceutical company’s stock valued at $25,315,000 after buying an additional 6,125 shares in the last quarter. IMS Capital Management increased its stake in Bristol-Myers Squibb by 15.2% in the first quarter. IMS Capital Management now owns 6,451 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 852 shares in the last quarter. Delta Asset Management LLC TN increased its stake in Bristol-Myers Squibb by 1.9% in the first quarter. Delta Asset Management LLC TN now owns 64,932 shares of the biopharmaceutical company’s stock valued at $4,148,000 after buying an additional 1,210 shares in the last quarter. Duncker Streett & Co. Inc. increased its stake in Bristol-Myers Squibb by 5.3% in the first quarter. Duncker Streett & Co. Inc. now owns 46,784 shares of the biopharmaceutical company’s stock valued at $2,988,000 after buying an additional 2,353 shares in the last quarter. Finally, Douglas Lane & Associates LLC acquired a new stake in Bristol-Myers Squibb during the first quarter valued at $25,824,000. 72.91% of the stock is owned by institutional investors.
Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.69% on Friday, reaching $55.43. 12,714,378 shares of the company were exchanged. The stock has a market capitalization of $92.62 billion, a price-to-earnings ratio of 32.42 and a beta of 0.74. The firm’s 50 day moving average price is $56.41 and its 200 day moving average price is $66.79. Bristol-Myers Squibb Co. has a 52 week low of $53.56 and a 52 week high of $77.12.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.03. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The firm earned $4.90 billion during the quarter, compared to analysts’ expectations of $4.60 billion. During the same quarter in the prior year, the company earned $0.53 EPS. The company’s revenue was up 17.2% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb Co. will post $2.63 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be given a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 annualized dividend and a dividend yield of 2.74%. Bristol-Myers Squibb’s payout ratio is presently 87.36%.
BMY has been the subject of several recent research reports. Credit Suisse Group AG downgraded shares of Bristol-Myers Squibb from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $86.00 to $63.00 in a research note on Sunday, August 7th. Morgan Stanley reissued a “hold” rating on shares of Bristol-Myers Squibb in a research note on Thursday, August 25th. Jefferies Group reissued a “hold” rating and issued a $57.00 price target (down from $69.00) on shares of Bristol-Myers Squibb in a research note on Monday, September 12th. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $75.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 27th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $69.00 price objective on shares of Bristol-Myers Squibb in a research note on Sunday. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $69.61.
In other news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total value of $1,228,392.00. Following the completion of the sale, the director now owns 334,499 shares of the company’s stock, valued at approximately $19,022,958.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.24% of the stock is currently owned by insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.